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Abstract. Background: Resistance to chemotherapy is a main
problem in cancer. The search for new effective compounds
that can increase sensitivity of resistant cells to existing
chemotherapeutics is an urgent need. In previous studies, it
has been demonstrated that steroid derivatives showed
promising results concerning their capacity to modulate
resistance of multidrug-resistant cell lines. Materials and
Methods: Steroid derivatives were studied for their growth-
inhibitory effect, cytotoxicity, reversal of multidrug resi stance,
apoptosis induction, and interaction with doxorubicin on
multidrug resistant human ATP-binding cassette, sub-family
B, member 1 (ABCB1) gene-transfected mouse T-lympho ma
cell line, and human PC-3 and LNCaP prostate cancer cell
lines in vitro. The steroidal interaction with P-glycopro tein
(ABCB1) was investigated by molecular docking. Results: Both
the activity of steroid derivatives on inhibition of the ABCB1
pump and their interaction with doxorubicin are dependent on
the substituent groups of the investigated steroidal structures.
Even though the investigated steroid derivatives were found to
have limited antiproliferative effect on the three different
cancer cell lines, in combination with doxorubicin, most of
them acted as good potentiators. The binding energies from
molecular docking ranged from −6.43 to −9.88 kcal/mol. The
predicted inhibition constants ranged from 0.1 to 10.1 μM. A
significant negative correlation was found between binding
energy and fluorescence activity ratio (R=−0.5, p=0.015).
Conclusion: The effective compounds can be candidates of
model molecules for possible applica tion in the treatment of
multidrug resistant cancer in rational drug design.
Prostate cancer has become the most common malignant
disease among men, and the second leading cause of male
cancer deaths in the USA. In the EU, prostate cancer is the
most common cancer in men and over 417,000 new cases are
diagnosed every year (1). Mortality from prostate cancer is
increasing disproportionately with the aging of the male
population within an overall population growth, and the
explanation for this alarming trend is still elusive (2). In
Hungary, for example, approximately 1250 men die from
prostate cancer each year (3).
It is known that testosterone and 5α-dihydrotestosterone
(5α-DHT) are androgens required for the development of
both normal prostate and prostate cancer. Prostate-specific
antigen (PSA), also known as gamma-seminoprotein or
kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in
humans by the KLK3 gene. PSA is a member of the
kallikrein-related peptidase family and is secreted by the
epithelial cells of the prostate gland (4). PSA is present in
small quantities in the serum of men with healthy prostates,
but is often elevated in the presence of prostate cancer or
other prostate disorders (4). Since the PSA test is used for
prostate cancer diagnosis, prostate cancer is detected at more
localized/early stages. Nevertheless, depending on the tumor
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differentiation stage, there is recurrence of the disease in 10-
40% of cases, which require further treatment. Once hormo -
nal therapy fails and disease progress to a castration-resistant
stage, the question of chemotherapy arises (5).
Multidrug resistance plays a crucial role in the failure of
treatment of all kinds of cancer, including prostate cancer.
For the past 40 years, researchers have been investigating the
various mechanisms by which cancer cells grown in tissue
culture become resistant to anticancer drugs (6). These
mechanisms include loss of a cell surface receptor acting as
a transporter for a drug to the inside of the cell, increased
metabolism of a drug and its detoxification, alteration by
mutation of its specific target(s) (7), and the elevated
expression of ATP-dependent drug-efflux pumps, therefore
reducing the accumulation of anticancer agents inside the
cell, among others (8).
The efficient synthesis of substituted androstane by A-ring
modification of picolinyldieneandrostane derivatives has
been reported (9). It has been suggested that this compound
specifically interacts with cytochrome P450 17α-hydrox -
ylase/17,20-lyase (CYP17) with similar affinity to the
abiraterone type of androstane drug clinically used in the
treatment of prostate cancer. It has been found that different
(17E)-picolinilidene-androstanes have selective antiprolifera -
tive activity against PC-3 prostate cancer cells, suggesting
that substituted steroidal compounds containing amino and
amido groups can be exploited as lead compounds in the
development of new anticancer compounds for the treatment
ANTICANCER RESEARCH 35: 2105-2112 (2015)
2106
Figure 1. Chemical structure of the steroid derivatives: 1: 20-N(N'-BOC-L-alanyl)-aminopregna-5,16-dien-3β-ol (MW=486.7); 2: 20-N (N'-BOC-
glycyl)-aminopregna-5,16-dien-3β-ol (MW=472.67); 3: 20-N(N'-BOC-L-phenylalanyl)-aminopregna-5,16-dien-3β-ol (MW=562.8); 4: 17β-N(N'-
BOC-L-prolyl)-aminoandrost-5-en-3β-ol (MW=486.7); 5: 3β-N(N'-BOC-L-phenylalanyl)-aminoandrost-4-en-17β-ol (MW=536.76); 6: 3β-N(L-
phenyl-alanyl)-aminoandrost-4-en-17β-ol hydrochloride (MW=473.11); 7: 17β-N(glycyl)-aminoandrost-5-en-3β-ol hydrochloride (MW=382.98);
8: 17β-N(L-alanyl)-aminoandrost-5-en-3β-ol hydrochloride (MW=397.01); 9: 17β-N(L-phenyl-alanyl)-aminoandrost-5-en-3β-ol hydrochloride
(MW=473.11); 10: 17β-N(L-prolyl)-aminoandrost-5-en-3β-ol hydrochloride (MW=423.04); 11: 17β-N(L-prolyl)-amino-5α-androstan-3β-ol
hydrochloride (425.06); 12: 20-N(L-prolyl)-aminopregna-5,16-dien-3β-ol hydrochloride (MW=449.09); 13: 16-N(n-propyl),N-acetyl-aminomethyl-
androst-5-en-3β,17β-diol (MW=403.5); 14: 20-amino-pregna-5,16-dien-3β-ol (MW=315.5); 15: 17-amino-5α-androstan-3β-ol (MW=291.48); 16:
3β-acethoxy,16N-acetyl,N-benzyl)aminomethylen-androst-5-en-17-one (MW=489.66); 17: 3β-acethoxy,16-(N-acethoxyethyl,N-ethyl)-aminomethylen-
5α-androstan-17-one (MW=487.64); 18: 16-(N-acetyl,N-benzyl)-aminomethylen-5α-androstan-3β,17β-diol (MW=451.65); 19: 3β-acethoxy,16E-
(N-acethyl,N-benzyl)-aminomethylen-5α-androstan-17β-ol (MW=493.69); 20: 16-(N-ethyl,N-p-sulphonylamidophenyl)-aminomethylene,3-methoxy-
estra-1,3,5(10)-trien-17-one (MW=504.7); 21: 16,17[d]-2’-aminopyrimidino,3-methoxy-estra-1,3,5(10)-triene (MW=335.45); 22: 3-cyclopen -
tyloxy,16-hydroxymethylen-estra-1,3,5(10)-trien-17-one (MW=366.5); 23: N-BOC-L-isoleucine-Opcp (MW=477.68); where BOC is terc-butil-oxy-
carbonyland Pcp ispentachloro-phenylester.
of prostate cancer (9, 10). Testosterone, progesterone and
other important natural steroids contain ketone groups in
position 3. Reduction of these groups into 3β-hydroxy causes
the loss of hormonal activity. In the case of estrogens,
alkylation of the 3-phenolic hydroxyl group results in similar
disappearance of their activity, therefore we also prepared
derivatives of 3β-hydroxy-pregnenes, -androstenes and 3-
alkoxy-estratrienes. Amide groups were chosen as substi -
tuents. We considered that amide groups were able to attach
to the peptide groups of proteins in cell membranes by
hydrogen bridges, initiating an effect on the cell mem brane
components, including the ATP-binding cassette, sub-family
B, member 1 (ABCB1) transporter. The starting steroids
were transformed into 3-, 16-, and 21- amino derivatives and
were acylated first with N- protected natural L amino acids.
More simple compounds were also prepared in which the
amide group is not a peptide-like moiety, but a simple acyl
amide, produced by acetylation of an alkyl-amino group
(compounds 13, 16-19, and 20, Figure 1).
In the present study, substituted steroids were synthesized
by using amido substituents and tested for their in vitro activity,
including antiproliferative and cytotoxic effect, their capacity
to inhibit the function of the ABCB1 membrane transporter,
apoptosis induction effect and activity in combination with
known chemotherapeutic agents, such as doxorubicin.
Materials and Methods
Compounds. Aminosteroids 14 and 15 were prepared from oximes
of the corresponding ketosteroids by sodium tetrahydroborate
reduction in the presence of NiCl3, as described previously (11). The
obtained aminosteroids were acylated with N-terc-butil-oxy-carbonyl
(BOC)-protected amino acids by mixed anhydride method (1-5) and
the protecting group was eliminated with dry hydrogen chloride in
dioxane solution, affording amine hydrochlorides 6-12. Alkyl-
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Figure 2. Interaction of four steroidal compounds (3, 5, 16 and 20) and verapamil at the transmembrane drug-binding pocket of ABCB1 (P-
glycoprotein). The amino acids involved in the interactions and their positions are shown.
aminomethylene steroids were prepared from 16-hydroxyme thylene-
17-ketosteroids and primary amines and acetylated with acetic
anhydride (compounds 16-20) (12, 13). The D-condensed
heterocyclic steroid 21 was prepared from 16-hydroxymethylene-3-
methoxy-estra-1,3,5(10)trien-17-one with guanidine (14, 15). The
16-aminomethyl-androstene derivative 13 was synthesized from the
corresponding 16-methylene-17-ketone by addition of n-propyl-
amine and selective O,O-desacetylation of the full acetylated product
(15). The chemical structures of the steroid derivatives evaluated in
this study are shown in Figure 1. Samples of the above mentioned
compounds were dissolved in dimethyl sulfoxide (DMSO) as 
2.0 mg/ml stock solutions. Verapamil as positive control, DMSO and
N-BOC-isoleucine-O-pentachloro-phenylester (compound 23) were
obtained from Sigma-Aldrich, St. Louis, MO, USA.
Cell cultures. The parental L5178 mouse T-cell lymphoma cells
(L5178 PAR) (ECACC cat. no. 87111908, obtained from the Food
and Drug Administration, Silver Spring, MD, USA) were trans fected
with pHa ABCB1/A retrovirus, as previously described by Cornwell
et al. (16). The multidrug- resistant (MDR) ABCB1-expressing cell
line L5178Y was selected by culturing the trans fected cells in
medium containing 60 ng/ml colchicine. L5178 PAR mouse T-cell
lymphoma cells and the MDR L5178Y human ABCB1-transfected
subline were cultured in McCoy’s 5A medium supplemented with
10% heat inactivated horse serum, 200 mM L-glutamine, and
penicillin-streptomycin mixture at 100 U/l and 10 mg/l, respectively.
The human prostate cancer cell lines PC-3 (ATCC® CRL-1435)
and LNCaP (ATCC® Cat. No. CRL-1740) were purchased from
LGC Standards GmbH, Wesel, Germany. The cells were grown in
RPMI-1640 medium with 2 mM L-glutamine and 10% fetal bovine
serum supplemented with antibiotics. Adherent human cancer cells
were detached with 0.25% trypsin and 0.02% EDTA for 5 min. The
cell lines were incubated in a humidified atmosphere (5% CO2, 95%
air) at 37˚C. The LNCaP cell line possesses androgen and oestrogen
receptors, while the PC-3 cell line does not contain either of these
receptors and is a suitable model for the hormone-resistant state.
Assay for antiproliferative effect of the compounds. The effects of
increasing concentrations of compounds on cell growth were
determined in 96-well flat-bottomed microtiter plates. The
compounds were serially diluted in 100 μl of McCoy’s 5A or RPMI-
1640 medium, respectively. A total of 6×103 mouse T-cell lymphoma
cells (PAR or MDR) or 1×104 PC-3 prostate cancer cells in 100 μl of
medium were then added to each well, with the exception of the
medium control wells. The culture plates were further incubated at
37˚C under 5% CO2 for 72 h. At the end of the incubation period,
20 μl of 3-[4.5-dimethylthiazol-2-yl]-2.5 diphe nyltetrazolium
bromide (MTT) (Sigma, St. Louis, MO. USA) solution (from a 5
mg/ml stock) were added to each well and after a further 4 h, 100 μl
of 10% sodium dodecyl sulfate (Sigma) in 0.01 N HCl were
measured into each well. The culture plates were further incubated at
37˚C overnight. The cell growth was determined by measuring the
optical density (OD) at 550 nm (ref. 630 nm) with a Multiscan EX
ELISA reader (Thermo Labsystem, Cheshire, WA, USA). In the
assay, the solvent did not have any effect on the cell growth at the
concentrations used for half maximal inhibitory concentration (IC50)
calculations. IC50 values and the standard error of the mean (SEM)
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Table I. Antiproliferative effect of steroid derivatives on L5178 mouse 
T-lymphoma parental cell line (PAR) and its L5178Y human ABCB1
gene- transfected subline (MDR), LNCaP and PC-3 prostate cancer
cells. Each experiment was repeated at least three times (data are
presented as the mean of three experiments).
Compound PAR MDR LNCaP PC3
IC50 SEM IC50 SEM IC50 SEM IC50 SEM
(μg/ml) (μg/ml) (μg/ml) (μg/ml)
1 10.87 0.63 15.82 0.78 13.41 0.99 12.04 1.24
2 9.80 0.24 19.13 0.1 13.09 1.41 12.49 1.09
3 >12.5 - 20.56 1.02 3.18 0.08 14.40 0.33
4 11.38 0.70 15.12 2.74 9.53 1.65 13.26 1.55
5 >12.5 - 26.20 0.91 15.82 0.51 >25 -
6 9.97 0.04 12.33 0.57 >25 - >25 -
7 9.36 0.40 11.75 0.30 >25 - >25 -
8 2.89 0.04 4.81 0.83 13.74 0.31 13.31 1.78
9 5.78 0.14 10.22 0.75 15.59 0.56 16.13 1.16
10 1.34 0.05 1.34 0.13 7.77 1.21 13.93 0.50
11 3.91 0.04 5.08 0.83 11.72 2.16 >12.5 -
12 0.99 0.01 1.12 0.16 4.68 0.41 5.21 0.66
13 1.47 0.23 8.83 2.84 >25 - >25 -
14 4.19 0.04 5.57 0.47 16.61 1.93 13.22 0.55
15 >12.5 - 16.32 1.52 >25 - >25 -
16 11.63 0.27 14.67 1.38 9.57 2.22 16.86 2.68
17 10.66 0.48 11.05 11.05 8.93 4.85 18.52 0.47
18 >12.5 - >25 - 3.62 0.01 15.29 2.01
19 >12.5 - >25 - 7.48 0.03 13.22 7.06
20 >12.5 - >25 - 16.27 6.69 >25 -
21 >12.5 - >25 - >25 - >25 -
22 11.71 0.16 6.80 1.86 10.15 2.57 14.54 0.61
23 >12.5 - >25 - 9.23 1.60 15,00 0.70
IC50: Half maximal inhibitory concentration; SEM: standard error of mean.
Table II. The comparison of the effect of aminosteroid derivatives on the
activity of the ATP-binding cassette, sub-family B, member 1 (ABCB1)
transporter in mouse T-lymphoma cells by flow cytometry. Compounds
were tested at 2 μg/ml. Verapamil was used as positive control at 10 μg/ml.
Compound FAR Compound FAR
Verapamil 17.21 13 58.79
1 54.28 14 2.20
2 37.64 15 1.76
3 59.28 16 75.48
4 37.92 17 16.69
5 29.07 18 77.41
6 9.21 19 52.90
7 10.21 20 45.82
8 1.47 21 1.07
9 39.14 22 10.43
10 1.19 23 12.26
11 2.77 DMSO 0.78
12 7.41
FAR: Fluorescence activity ratio, calculated using the equation given in
the Material and Methods; DMSO: dimethyl sulfoxide.
of triplicate experiments were calculated using GraphPad Prism
software version 5.00 for Windows with nonlinear regression curve
fit (GraphPad Software, San Diego, CA, USA; www.graphpad.com).
Assay for reversal of MDR in mouse T-lymphoma cells. The cell
density of L5178 MDR and L5178Y PAR cell lines was adjusted to
2×106 cells/ml, and they were re-suspended in serum-free McCoy’s
5A medium and distributed in 0.5 ml aliquots into Eppendorf
centrifuge tubes. The tested compounds were added at a final
concentration of 2 μg/ml and the samples were incubated for 10
minutes at room temperature. Verapamil (Sigma) was applied as
positive control (16) at 10 μg/ml. DMSO was added to the negative
control tubes at the same volume used for the tested compounds.
No activity of DMSO was observed. Next, 10 μl (5.2 μM final
concentration) of the fluorochrome and ABCB1 substrate rhodamine
123 (Sigma) was added to the samples and the cells were incubated
for a further 20 minutes at 37˚C, then washed twice and re-
suspended in 0.5 ml phosphate buffer saline (PBS) for analysis. The
fluorescence of the cell population was measured with a Partec
CyFlow® flow cytometer (Partec, Münster, Germany). The percen -
tage mean fluorescence intensity was calculated for the treated
MDR cells as compared with the untreated cells. A fluorescence
activity ratio (FAR) was calculated based on the following equation
(16) on the basis of the measured fluorescence values:
A checkerboard microplate method was applied to study the effect
of drug interactions between the steroidal derivatives and chemothe -
rapeutic drug doxorubicin on PC-3 cancer cells. The dilutions of
doxorubicin were made in a horizontal direction in 100 μl, and the
dilutions of the compounds vertically in the microtiter plate in 50 μl.
The cells were re-suspended in culture medium and distributed into
each well in 50 μl containing 6×103 cells. The plates were incubated
for 72 h at 37˚C in a CO2 incubator. The cell growth rate was
determined after MTT staining, as described above. Combination
index (CI) values at 50% growth inhibition (ED50) were determined
using CompuSyn software (http://www.combosyn. com; ComboSyn,
Inc., Paramus, NJ, USA) to plot four to five data points for each
ratio. CI values were calculated by means of the median-effect
equation (17), where CI <1, CI=1, and CI >1 represent synergism,
additive effect (or no interaction), and antagonism, respectively.
Apoptosis assay. The capacity of the compounds to induce apoptosis
was investigated using human PC-3 prostate cancer cell line. The cell
density was adjusted to 5×105 cells/ml and cells were distributed in
0.5 ml aliquots into 24-well plates. The apoptosis inducer 12H-
benzo[α]phenothiazine (M627) was kindly provided Professor
Noborul Motohashi (Meiji Pharmaceutical University, Tokyo, Japan)
used as positive control at 25 μg/ml. Compounds were tested at 4
μg/ml. Wells containing no M627 or steroidal compounds served as
negative controls. The cells were incubated at 37˚C for 3 h and at the
end of the incubation period, the culture medium was removed, and
the cells were washed with PBS and 0.5 ml of fresh culture medium
was added to the cells. Samples were then transferred to 24-well
culture plates and further incubated overnight at 37˚C under 5% CO2.
Apoptotic activity of the compounds was evaluated using Annexin-V
FITC Apoptosis Detection Kit (Cat. No. PF 032; Calbiochem, Merck
KGaA, Darmstadt, Germany) according to the manufacturer's
instructions. The fluorescence of cell population was analyzed
immediately using a Partec CyFlow® flow cytometer (Partec).
Molecular docking. The 2D structures of the chemical entities were
drawn and later energy-minimized into 3D structures using Corina
Online Demo (18). All 3D structures were saved in PDB format
ready to be docked. Molecular docking was conducted following a
protocol previously reported by us (19). In brief, the X-ray crystal -
lography-based structure of mouse P-glycoprotein and the homo -
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Figure 3. Correlation between lowest binding energies calculated by
molecular docking and drug uptake data shown in Table II. (Pearson
correlation test; R=−0.5; p=0.015).
Table III. Type of interaction between 16 amidosteroid derivatives and
doxorubicin against the PC-3 prostate cancer cell line.
Compound Ratioa CIb Interaction
1 5:1 0.44 Synergism
2 5:1 0.47 Synergism
3 10:1 0.91 No interaction
4 5:1 0.28 Strong synergism
8 10:1 0.40 Synergism
9 10:1 0.17 Strong synergism
10 10:1 0.26 Strong synergism
12 5:1 0.55 Synergism
14 10:1 0.29 Strong synergism
16 10:1 0.53 Synergism
17 10:1 0.38 Synergism
18 10:1 0.96 No interaction
19 20:1 0.61 Synergism
22 20:1 0.27 Strong synergism
23 20:1 0.30 Synergism
aData are shown as the best combination ratio between doxorubicin and
the tested compounds, respectively. bCombination index (CI) values at
50% of growth inhibition (ED50) were determined by using CompuSyn
software to plot four to five data points for each ratio. CI values were
calculated by means of the median-effect equation, where CI <1, CI=1,
and CI >1 represent synergism, additive effect (i.e. no interaction), and
antagonism, respectively.
logy-modelled structure of human P-glycoprotein were set as the
rigid receptor molecule. The X-ray crystallography protein-based
structures were first processed with AutodockTools-1.5.6rc3 (20) by
the addition of essential hydrogen atoms to overcome the problem
of incomplete structures due to missing atoms or water molecules.
The output file after preparation was in PDBQT format, where
information about atomic partial charges, torsion degrees of freedom
and different atom types were added, e.g. aliphatic and aromatic
carbon atoms or polar atoms forming hydrogen bonds. A grid box
was then constructed to define docking spaces. The dimensions of
the grid box were set around the whole P-glycopro tein molecule
such that the ligand was able to freely move and rotate in the
docking space. The grid box consisted of 126 grid points in all three
dimensions (X, Y and Z) each separated by a distance of 1 Å.
Energies at each grid point were then evaluated for each type of
atom present in the ligand, and the values were then used to predict
the energy of a particular ligand configuration. Docking parameters
were set to 250 runs and 2,500,000 energy evaluations for each
cycle. Docking was performed by Autodock4 (20) using the
Lamarckian algorithm. The corresponding binding energies and the
number of conformations in each cluster were attained from the
docking log files. The binding energies of the 23 compounds were
correlated with their FARs using Pearson correlation coefficient.
Results
Twenty-three derivatives were synthesized and their antiproli -
ferative (Table I) and cytotoxicity activities were studied on
PAR, MDR, LNCaP, and PC-3 cell lines. Evaluation of the
antiproliferative activity of the compounds revealed that
compounds 8 and 10-14 were the most active against the
parental mouse T-lymphoma cell line, with IC50 values of less
than 5 μg/ml. With the exception of compounds 9 and 13, all
the above-mentioned compounds and compound 22 were also
active against the MDR cell line. With respect to the two
different prostate cancer cell lines, the most effective
compounds were 3, 12, 18, 19, and 23 against LNCaP cells,
and compound 12 against PC-3 cells. Therefore, as per the
results above, compound 12 was the only one with strong
activity against all four cell lines studied.
The capacity of the compounds to inhibit the ABCB1
transporter was studied on MDR mouse T-lymphoma cells
that were transfected with the human ABCB1 gene (Table II).
The MDR-reversal effect was studied at 2 μg/ml. Amino -
steroid compounds acylated with BOC amino acids 1-5 and
9 and even simple N-acetyl derivatives 13, 16, 18, 19
presented remarkable activity in the reversal of MDR of the
MDR mouse T-lymphoma cell line, with FAR values of
between 29 and 77. Steroids containing free amino groups
or amine-hydrochloride substituents showed weaker or no
activity on MDR reversal as measured by accumulation of
rhodamine-123. Interestingly, compound 12 presented only
mild inhibition at the concentration used. Concerning the
activity of compounds expressed in μM, the most active
compound was compound 18 because at a concentration of
4.4 μM, the FAR of compound 18 was 77.41. Moreover,
compounds 1, 3, 13, 16, and 19 were also highly active. 
The apoptosis-inducing effect of the compounds was
measured at the non-toxic concentration of 4 μg/ml on the
PC-3 cell line (data not shown). It was observed that there
was no relevant activity of these compounds on apoptosis
induction: the proportion of early apoptosis was between 1-
6%, late apoptosis and necrosis between 1-5%, and cell death
was around 1%. There was no significant difference when
comparing these data with those of the untreated control. 
The activity of the steroidal compounds in combination
with doxorubicin was analyzed using checkerboard assay for
PC-3 cells (Table III). It was observed that the effect of these
compounds on the activity of doxorubicin ranged from
ineffective to strongly synergistic. Strongly synergistic effects
of modified steroids with doxorubicin were produced in the
case of five compounds, namely 4, 9, 10, 14, and 22. Synergy
was found with derivatives 1, 2, 8, 12, 16, 17, 19, and 23. Two
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Table IV. Results of molecular docking of steroidal compounds to the
transmembrane proteins. Lowest binding energy, predicted inhibition
constant (Pki) and amino acids (AA) involved in hydrogen bonding for
each compound are shown. Each docking experiment was repeated three
times (data are presented as the mean and SEM).
Compound Binding Pki (μM) Hydrogen bond-
Energy (kcal/mol) forming AA
Mean SEM Mean SEM
Verapamil −5.64 0.41 0.9 0.2 Val 862
1 −7.94 0.08 1.5 0.2 Gln 946
2 −7.71 0.19 2.4 0.7 -
3 −8.34 0.26 0.8 0.3 -
4 −7.66 0.02 2.4 0.1 Gln 347
5 −8.39 0.06 0.7 0.1 Tyr 953
6 −6.97 0.08 7.8 1.0 -
7 −6.44 0.01 18.9 0.2 Asp 188; Gln 195
8 −6.55 0.20 9.7 0.1 -
9 −8.49 0.06 0.6 0.1 Gln 347
10 −6.81 0.02 10.1 0.2 Asp 188
11 −7.30 0.06 4.5 0.4 Thr 945
12 −7.67 0.06 2.4 0.2 Asp 188; Gln 195
13 −7.31 0.09 4.4 0.7 -
14 −7.80 0.01 1.9 0.0 -
15 −7.20 0.00 5.5 0.3 Asp 188
16 −8.54 0.10 0.6 0.1 -
17 −8.30 0.18 0.9 0.2 -
18 −9.04 0.01 0.2 0.0 Asp 886; Lys 934
19 −9.27 0.03 0.2 0.0 -
20 −9.88 0.07 0.1 0.0 -
21 −8.23 0.12 1.1 0.0 -
22 −9.84 0.02 0.1 0.0 -
23 −6.43 0.10 19.5 3.5 -
compounds, 3 and 18, were ineffective in this study. The IC50
of compounds 5-7, 11, 13, 15, 20 and 21 could not be
calculated and this fact did not allow the determination of the
degree of interaction of these compounds with doxorubicin. 
We investigated in silico the interaction of the panel of
steroid compounds with P-glycoprotein, using verapamil as a
positive control. All 23 compounds had binding energies
lower than that of verapamil (Table IV). The binding ener gies
ranged from −6.43 to −9.88 kcal/mol. The predicted inhibi -
tion constants ranged from 0.1 to 10.1 μM. The inter action of
four of the test compounds, the control compound verapamil
and the amino acids involved are shown in Figure 2. The
binding sites of the compounds were found to coincide with
the binding site of verapamil. The binding energies of the 23
compounds were correlated with their FARs using Pearson
correlation coefficient (Figure 3). A significant negative
correlation was found between the binding energies of the 23
compounds and their FARs (R=−0.5, p=0.015). 
Discussion
The MDR transporters are one of the main causes of cancer
treatment failures (21). Modulation of efflux pump-related
mechanisms, in order to increase the activity of existing
chemotherapeutics to which cancer becomes resistant, is one
of the possible ways to overcome resistance. In our
investigation, modified steroid derivatives without hormonal
activity were chosen to achieve this effect.
Based on our studies, compounds 8, 10-12, 14, and 22
had effective antiproliferative activity against MDR mouse
T-lymphoma cells. These compounds are aminoacylamide
salts applied to three different steroid skeletons (androstane,
androstene, and preganadienes). Compound 22 is an estrone
ether derivative and it has a bidentate α-hydroxymethylene-
ketone arrangement on the D-ring, rendering the possibility
of a 1,4-hydrogen donor-acceptor connection. On the other
hand, compounds 3, 12, 18, 19, and 23 proved to be
effective in the antiproliferative assays against the LNCaP
prostate cell line.
In the MDR-reversal studies, the majority of the investi -
gated compounds were effective: 1-5, 9, 13, 16-20 (Table II).
Compounds 6, 8, 10-12, 14, 15, and 21 had only a weak
effect. These latter molecules either contain amine hydro -
chloride, or have special structures; the latter three compounds
(14, 15, and 21) are estrone ether derivatives. Aminosteroids
with basical primary amino groups had practically no effect.
The compounds of remarkable activity contain four different
steroid skeletons, four different amino acyl parts (glycyl,
alanyl, phenylalanyl and prolyl) and, in the case of the simpler
molecules, three different alkyl (propyl, benzyl and
acethoxyethyl) moiety. The only common structural element
amongst them is the amide part, deriving from an α-amino
acid or acetic acid. In compounds 18 and 19, a double bound
is present in the A and B rings, in addition to there being no H
atom at the C-5 position. This H atom either induces or is
responsible for conformational changes in the four condensed
rings with chair-like structure. In the case of compound 13,
the hydrophobic steroid containing acyl-amide can help
binding to the beta-turn of the ABCB1 protein. We suppose
that the biologically active N-protected BOC compounds bind
to particular beta-turns of the ABCB1 transporter. Possibly,
there are preferred amino acids in the beta-turns that may have
a key role in maintaining the functionally active conformations
of the ABCB1 transporter localized in the cell membrane.
Molecular docking is an effective computational technique
which estimates the binding energy of a compound to the
target protein. A scoring system is used to detect the ideal
docking configuration. The amino acids involved in
hydrophobic and hydrogen bond interactions are also predicted
by the algorithm. Our results from molecular docking suggest
that the compounds tested inhibit P-glycoprotein activity
through binding to the drug-binding pocket, which is the same
binding site as for verapamil. Most of the compounds with
high activity, and verapamil, share one or more amino acids
in their binding sites. It appears that there is a significant
correlation between the binding energies of the compounds
and their FARs. It can be suggested that molecular docking
might be used as a tool predictive of the activity of steroidal
compounds as inhibitors of P-glycoprotein. 
A large number of compounds were able to enhance the
activity of doxorubicin against the PC-3 cell line in combina -
tion experiments. Based on our results, compound 9 could
be a lead compound for further investigations related to
combined chemotherapy; in addition, compound 12 might be
a promising candidate as an effective antiproliferative 
che mo therapeutic agent.
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